OcuTerra Therapeutics’ investigational eye drops failed to improve disease severity or progression in a phase 2 diabetic retinopathy trial, prompting the Boston-based biotech to look at strategic ...
Vivoryon Therapeutics’ glutaminyl cyclase inhibitor has failed a second phase 2 Alzheimer’s disease study this year, leaving the German biotech trying to find a silver lining in the drug’s potential ...
The highest-grossing film in India, 'Pushpa 2: The Rule,' the highly anticipated sequel to 'Pushpa: The Rise,' was a global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback